Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)

NCT05455619 is registered in ClinicalTrials.gov with SynDevRx, Inc. as lead sponsor.

NCT NCT05455619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05455619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)
Lead sponsor
SynDevRx, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 26, 2022
Completion date
March 31, 2027
Enrollment
52 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2-negative breast cancer, metastatic breast cancer